Krystal Biotech director Gangolli Julian S received 1,658 derivative securities across two transactions dated Sep. 14, with each priced at $0 per share. The award changes the director’s reported derivative position and gives investors a specific record of the transaction type, date and stated price.
Key Highlights
- The transactions were classified under code A, which denotes an award or grant.
- Gangolli Julian S completed the transactions on 14 September 2026.
- The derivative securities carried a stated price of $0 per share.
Krystal Biotech, Inc. (NASDAQ: KRYS) awarded director Gangolli Julian S a total of 1,658 derivative securities. The transactions were dated 14 September 2026 and carried a stated price of $0 per share, marking a change in the director’s reported derivative position. The award was recorded across two separate transactions. Both entries used transaction code A, the classification for an award or grant. Gangolli Julian S was identified as a director of Krystal Biotech, Inc. The securities were derivative instruments rather than common stock, and the stated per-share price was $0. The transaction date was 14 September 2026.
Award Details and Transaction Classification
The entries were recorded separately but carried the same transaction classification. Code A identifies the activity as an award or grant, rather than an open-market purchase or sale. Gangolli Julian S was the individual associated with the transactions, and Krystal Biotech, Inc. was the company named in the record. The transaction record therefore identifies the quantity, classification, date and price attached to the director’s derivative securities award.
FAQs
Q: What did Gangolli Julian S receive from Krystal Biotech?
A: Gangolli Julian S received 1,658 derivative securities from Krystal Biotech. The securities were awarded through transactions classified under code A.
Q: When did the Krystal Biotech director transactions occur?
A: The transactions involving Gangolli Julian S were dated 14 September 2026. They were recorded as two separate transactions.
Q: What price was listed for the derivative securities?
A: The derivative securities carried a stated price of $0 per share. The record associated that price with the award transactions involving Gangolli Julian S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.